Chimeric and mutationally stabilized tumor-specific B1, B3 and B

Details Chimeric and mutationally stabilized tumor-specific B1, B3 and B Chimeric and mutationally stabilized tumor-specific B1, B3 and B

1994-10-28

1999-11-09

Hutzell, Paula K.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

5303873, 5303877, 5303897, 5303917, 4241331, 4241351, 4241381, 4241551, 4241741, 4241811, 4241831, 435328, 435344, 435 696, 435 697, 435 911, 536 234, A61K 39395, C07M 2104

Patent

active

059817267

ABSTRACT:
This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibodies B1 and B5. The invention also provides for a number of stabilizing mutations of the Lewis.sup.Y -binding monoclonal antibody B3. In addition, the invention provides for methods of detecting cells bearing a Lewis.sup.Y antigen in a patient and for methods of killing or inhibiting the growth of cells bearing a Lewis.sup.Y antigen in a patient.

REFERENCES:
patent: 4545985 (1985-10-01), Pastan et al.
patent: 5242813 (1993-09-01), Pastan et al.
patent: 5258498 (1993-11-01), Houston et al.
Proceedings of the National Academy of Sciences of the USA, vol. 88, No. 19, Oct. 1,1991 Washington DC, USA, pp. 8616-8620, U. Brinkmann et al. `B3 (Fv)-PE38KDEL, asingle-chain immunotoxin that causes complete regression of a human carcinoma in mice`, cited in the application, see abstract, see figures 1,2.
Bioconjugate Chemistry, vol. 5, No. 4, Jul. 1994 Washington, DC, USA, pp. 321-326, XP 000564453 I. Benhar et al. `Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization.`, cited in the application, see abstract, see figure 1.
Cancer Research, vol. 53, No. 2, Jan. 15, 1993 Philadelphia, PA, USA, pp. 334-339, P. Friedman et al. `BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.`, see abstract, see discussion.
The Journal of Immunology, vol. 152, No. 5, Mar. 1, 1994 Baltimore, MD, USA, pp. 2377-2384, C. Siegall et al., `In vitro and in vivo characterization of BR96 sFv-PE40.` see abstract.
Bast et al. J. Clin. Invest., 68: 1331-1337 (1981).
Batra et al., J. Biol. Chem., 265: 15198-15202 (1990).
Batra et al., Proc. Natl. Acad. Sci. USA 86: 8545-8549 (1989).
Bird et al., Science, 242: 423-26 (1988).
Brinkmann et al. Proc. Natl. Acad. Sci. USA, 89: 3075-3079 (1992).
Brinkmann and Pastan, Biochem. Biophys. Acta., 1198: 27-45 (1994).
Chaudhary et al., Proc. Natl. Acad. Sci. USA 87: 9491-9494 (1990).
Chaudhary et al., Proc. Natl. Acad. Sci. USA 87: 1066-1070 (1990).
Chaudhary et al., Nature, 339: 394-397 (1989).
Hartman et al. E.M.B.O.J. 3: 3023-3030 (1984).
Hellstrom et al. Cancer Res., 50: 2183-2190 (1990).
Hoess et al., Gene, 128: 43-49 (1993).
Houston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988).
Kondo et al., J. Biol. Chem., 263: 9470-9475 (1988).
Pai et al., Proc. Natl. Acad. Sci. USA, 88: 3358-3362 (1991).
Pastan et al. Cancer Res., 51: 3781-3787 (1991).
Willingham et al. Proc. Natl. Acad. Sci. USA, 84: 2474-2478 (1987).

Affiliated with

Also associated with

Rating

Chimeric and mutationally stabilized tumor-specific B1, B3 and B does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric and mutationally stabilized tumor-specific B1, B3 and B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric and mutationally stabilized tumor-specific B1, B3 and B will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1457732